

UNDERSTANDING THE MOLECULAR MECHANISM OF ACTION OF WITHANOLIDES FROM ASHWAGANDHA

SHASHANK PRAKASH KATIYAR



**DEPARTMENT OF BIOCHEMICAL ENGINEERING AND BIOTECHNOLOGY
INDIAN INSTITUTE OF TECHNOLOGY DELHI**

APRIL 2017

©INDIAN INSTITUTE OF TECHNOLOGY DELHI (IITD), NEW DELHI, 2017

UNDERSTANDING THE MOLECULAR MECHANISM OF ACTION OF WITHANOLIDES FROM ASHWAGANDHA

by


Shashank Prakash Katiyar

Department of Biochemical Engineering and Biotechnology

Submitted

In fulfillment of the requirements of the degree of Doctor of Philosophy

to the



Indian Institute of Technology Delhi

APRIL 2017

*This thesis is dedicated to my grandparents, who laid the foundation long back by
educating my parents*

*The reality cannot be the Truth,
because the reality is created by perception and perception is forged*

CERTIFICATE

This is to certify that the thesis entitled '**Understanding the molecular mechanism of action of withanolides from Ashwagandha**' being submitted by **Mr. Shashank Prakash Katiyar** to the Indian Institute of Technology Delhi for the award of the degree of '**Doctor of Philosophy**', is a record of the bona fide research work carried out by him, which has been prepared under my supervision in conformity with the rules and regulations of the Indian Institute of Technology Delhi. The research reports and the results presented in this thesis have not been submitted for any degree or diploma in any other University or Institute.

Dr. D. Sundar

Associate Professor

Department of Biochemical Engineering and Biotechnology

I.I.T Delhi

ACKNOWLEDGEMENTS

Firstly, I would like to express my sincerest gratitude to my advisor Dr. D Sundar for the uninterrupted support during my Ph.D. study and related research, for his patience, motivation, and immense knowledge. His guidance helped me throughout the research and writing of this thesis. I could not have imagined having a better advisor and mentor for my Ph.D. study. Also, I would like to thank Dr. Renu Wadhwa and Dr. Sunil Kaul from AIST, Japan for providing me an opportunity to perform *wet lab* experiments and for their valuable advice.

My sincere thankfulness to the rest of my thesis committee: Prof. Virendra S. Bisaria, Dr. Ritu Kulshreshtha, and Prof. Tapan Kumar Chaudhuri (School of Biological Sciences, IITD), for not only their insightful comments and encouragement, but also for the questions which motivated me to widen my research from various perspectives.

I thank my fellow lab-mates for the stimulating discussions, for tiring working hours, the sleepless nights we were working together before deadlines, and for all the fun we have had in the last few years. I would also like to thank all my lab mates for proof reading the thesis. I am very grateful to Ms. Shayoni Dutta, Ms. Jaspreet Dhanjal, Ms. Vidhi Malik, Ms. Anjani Kumari, Ms. Kamya Singh, Mr. R. Navaneethan, Mr. Sai Krishna, Mr. Kamlesh Kumar and all the people who shared the lab with me at some point of time during this long journey, for ensuring that I never lost hope and in keeping the lab environment full of energy, love and fun. It was pleasure to meet all these people.

Last but the most importantly, I cannot thank enough to my family: my father Mr. Jay Prakash Katiyar, my mother Ms. Sunita Katiyar, my sister Ms. Shweta Katiyar and my wife Ms. Rashmi Prava Mohanty for always being supportive all the times and in believing in me. Your faith in me has always fueled my motivations.

Shashank Prakash Katiyar

ABSTRACT

The plant Ashwagandha (*Withania somnifera*) is held in high repute in traditional Indian medicine system Ayurveda, largely due to the presence of withanolides such as withaferin-A, withanolide-A, withanone and many more. The withanolides are a group of naturally occurring C-28 steroidal lactones that are built on an intact or rearranged ergostane framework. Apart from withanolides, several groups of other chemical constituents such as alkaloids, flavonoids, tannin etc. have been identified, extracted, and isolated from this plant. Withanolides have diverse pharmacological properties ranging from anti-tumor, anti-inflammatory, anti-stress, anti-oxidant, immuno-modulatory, hemopoetic, cardio-protective and neuro-protective in nature. Because of these properties, Ashwagandha has been compared to ginseng and thus is also referred to as Indian ginseng.

Recently, withanolides have gained importance for testing on cancer cells and they are found to affect the functional activity of cancer-related proteins. Not only the potential of withanolides against cancer cells makes these natural compounds a candidate of interest, but also the recent reports of their selectivity against cancer cells, demands an urgent need to explore the potential of withanolides and the basis of such selectivity. Though the therapeutic effects of these withanolides are well documented, the detailed specific action-mechanisms on the respective disease-associated targets are still largely unknown. The focus of the research in this thesis was to elucidate the mode of action of withanolides on various crucial therapeutic targets using computational techniques. The mechanism of action of withanolides has been investigated using computer simulations and attempts were made to conduct experimental validations as well. The modes of selectivity towards cancer cells by withanolides at the molecular level has also been studied in detail. The permeable nature and metabolic fate of the withanolides to understand their drug-like potentials has also been explored. In the process of understanding the mechanism of withanolides, molecular mechanisms of proteins and their interactions with other natural molecules have also been documented.

Overall, the research focus of this PhD project was directed towards broadening our understanding of the action mechanism of withanolides by exploring their interactions with biological targets and validating their effect on different pathways.

सारांश

अश्वगंधा के पौधे का पारंपरिक भारतीय चिकित्सा प्रणाली में मुख्यतः विथानोलाइड, जैसे की विथफेरिन-ए, विथानोलाइड-ए, विथानोन, एवं अन्य कई विथानोलाइड की वजह से उच्च स्थान है। विथानोलाइड प्राकृतिक रूप से पाये जाने वाले २८-कार्बन से बने स्टेरॉइडल लैक्टोन हैं, जोकि स्थिर तौर पर बरकरार रहने वाले या पुनर्व्यवस्थित होने वाले एर्गोस्टोन की रूपरेखा पर बने होते हैं। इस पौधे में विथानोलाइड के अलावा भी कई अन्य रासायनिक घटक जैसे कि अल्कलॉइड, फ्लैवोनोंड, टैनिन पहिचाने एवं अलग किये गए हैं। इस पौधे में विथानोलाइड के अलावा भी कई अन्य रासायनिक घटक जैसे कि अल्कलॉइड, फ्लैवोनोंड, टैनिन पहिचाने एवं अलग किये गए हैं। विथानोलाइड में एंटी-ट्यूमर से लेकर एंटी-स्ट्रेस, एंटी-ऑक्सीडेंट, इम्युनोमोड्यूलेटरी, हेमोपोइटिक, कार्डियो-प्रोटेक्टिव, एवं न्यूरो-प्रोटेक्टिव तक भांति प्रकार की औषधीय गुण पाये जाते हैं। इसी प्रकार के गुणों की वजह से, अश्वगंधा की तुलना जिनसिंग से की जाती है और इसी कारणवस यह भारतीय जिनसिंग कहलाता है।

हाल ही में, विथानोलाइड की महत्वपूर्णता को कैंसर कोशिकाओं पर परिक्षण की वजह से बढ़ावा मिला है और वे कैंसर से जुड़े हुए प्रोटीनों की कार्यात्मक गतिविधि को प्रभावित करते हुए पाए गए हैं। सिर्फ कैंसर कोशिकाओं के विरुद्ध विथानोलाइडों की क्षमता ही इन प्राकृतिक यौगिकों को रिचिपूर्ण नहीं बनाता, बल्कि हालही में इनकी चयनकता के बारे में आयी सूचनाएं इनकी अन्य क्षमताओं की खोज की एवं इस प्रकार के चयनिक क्षमताओं के आधार की खोज की तात्कालिक मांग करती हैं। यद्यपि, इन विथानोलाइडों के उपचारात्क प्रभाव अच्छी तरह से प्रलेखनित हैं, इनके विस्तारपूर्ण रोग सम्बंधित विशिष्ट क्रिया-तंत्र का वर्णन अभी भी अज्ञात है। इस शोध का केन्द्रीकरण, अभिकलनात्मक पद्धतियों के द्वारा विथानोलाइडों की विभिन्न महत्वपूर्ण चिकित्सीय लक्ष्यों की क्रियाओं के माध्यम की विस्तृत व्याख्या करना था। विथानोलाइडों की क्रिया पद्धतियाँ अभिकलनात्मक अनुकरणों के द्वारा निरूपित की गई हैं एवं प्रयोगों के द्वारा पुष्टिकरण करने का प्रयास भी किया गया है। पुष्टिकरण करने का प्रयास भी किया गया है। विथानोलाइड द्वारा कैंसर कोशिकाओं के प्रति चयनकता भी विस्तार से निरूपित की गई है। विथानोलाइड की पारगम्य प्रकृति एवं मेटाबोलिक भाग्य को भी इनके औषधी बनाने की संभावना को समझने हेतु खोजा गया है। विथानोलाइड की यांत्रिक क्रिया को समझने की प्रक्रिया में, कई प्रोटीनों की यांत्रिक क्रिया एवं उनके अन्य प्राकृतिक घटकों के साथ पारस्परिक संबंधों को भी निरूपित किया गया है।

सम्पूर्णतः, इस शोध पत्र का केंद्र, विथानोलाइडों के साथ जैविकीय लक्ष्यों के संबंधों की जानकारी से एवं उनके प्रभावों का कई पाथवे पर अध्ययन के द्वारा विथानोलाइडों के क्रिया तंत्र के बारे में अपनी समझ को बढ़ाने की दिशा में था।

CONTENTS

<i>Certificate.....</i>	<i>i</i>
<i>Acknowledgement.....</i>	<i>iii</i>
<i>Abstract.....</i>	<i>v</i>
<i>List of Figures.....</i>	<i>xi</i>
<i>List of Tables.....</i>	<i>xv</i>
<i>List of Equations.....</i>	<i>xvii</i>
<i>List of Abbreviations and Acronyms.....</i>	<i>xix</i>
1 Introduction.....	1
1.1 Background.....	3
1.2 Withanolides	4
1.2.1 Structure and Diversity	5
1.2.2 Therapeutic potentials of withanolides	7
1.2.3 Effect of withanolides on cancer	8
1.2.4 Importance of understanding the molecular interactions between withanolides and biological target molecules	11
1.2.5 Selectivity of withanolides	11
1.2.6 Key withanolides studied in this thesis	12
1.3 Motivation.....	12
1.4 Definition of the problem.....	13
1.5 Objectives.....	14
2 Molecular mechanism of the anti-cancer potential of withanolides.....	15
2.1 Introduction.....	17
2.2 General Methodology.....	20
2.2.1 Identification of biological targets	22
2.2.1.1 Literature survey	23
2.2.2 Identification of structures of biological molecules	24
2.2.3 Identification of molecular binding interfaces	26
2.2.3.1 Binding site prediction for withanolides	27
2.2.3.2 Prediction of binding site interface between protein-protein or protein-DNA/RNA molecules	28
2.2.4 Prediction of molecular complexes	29
2.2.4.1 Generation of the structural conformation of withanolides	29

2.2.4.2 Protein-Ligand docking	30
2.2.4.3 Protein-Protein / Protein-DNA docking	31
2.2.5 Study of molecular dynamics	32
2.2.6 Free energy calculations	34
2.2.7 Analysis of the structure and dynamics	36
2.2.8 Experimental validations of <i>in silico</i> results	36
2.2.8.1 Cell culture and colony forming assays	37
2.2.8.2 Cytotoxic and cell growth inhibition assay	37
2.3 Mechanism of anti-angiogenic and anti-metastatic properties of Wi-A and WN.....	38
2.3.1 Background of this study	38
2.3.2 Computational Methods	41
2.3.3 Results	42
2.3.3.1 ssDNA/RNA binding site of hnRNPK at KH3 domain.....	42
2.3.3.2 Docking of Wi-A and WN at the ssDNA/RNA binding site of hnRNP-K.....	43
2.3.3.3 Dynamics of Wi-A and WN binding at the KH3 domain of hnRNP-K	46
2.3.4 Discussion	48
2.4 Mechanism of anti-metastatic property of withanolides by interfering with chaperon function of HSP90 protein	50
2.4.1 Background of this study	50
2.4.2 Computational methods	52
2.4.3 Results and Discussion.....	53
2.4.3.1 Binding site at the C-Terminal of HSP90.....	53
2.4.3.2 Binding of TA, Wi-A and WN at the C-terminal of HSP90.....	53
2.4.3.3 Interactions of TA, Wi-A and WN at the C-terminal of HSP90.....	55
2.4.3.4 Binding of other withanolides at the C-terminal of HSP90.....	59
2.5 Cytotoxicity of withaferin-A against the cancer cells	60
2.5.1 Experimental inputs from DAILAB@AIST	62
2.5.2 Computational Methods	65
2.5.3 Results	66
2.5.3.1 Comparison of DNA binding affinity between Myc and Mad	66
2.5.3.2 Binding of Wi-A with Myc and Mad	67
2.5.3.3 Effect of the Wi-A binding on Myc and Mad.....	67
2.5.3.4 Wi-A binding enhanced the binding of DNA with Mad	70
2.5.4 Discussion	71

2.6 Conclusion of mechanism of anti-cancer properties of withanolides	73
3 <i>Selective action of withanolides in normal and cancer cells</i>.....	75
3.1 Introduction	77
3.2 Computational methods.....	81
3.3 Results and Discussion	82
3.3.1 p53 ^{143A} is resistant against withanolides	82
3.3.2 Selective binding of Wi-A with p53 ^{220C} mutant.....	83
3.3.2.1 The structural differences between p53 ^W and p53 ^{220C}	83
3.3.2.2 Binding of withanolides with p53 ^C near Tyr 220	85
3.3.2.3 Binding of withanolides with p53 ^{220C} at the site of mutation	86
3.3.2.4 Low dose of Wi-A selectively kills the mutant p53 Y220C cells	90
3.3.3 Withanolides are non-selective towards p53 ^{249S} , p53 ^{273C} , and p53 ^{273H}	91
3.3.3.1 In silico Analysis of loss of p53 ^{249S} function.....	91
3.3.3.2 Binding mode of withanolides are similar for both p53 ^W and p53 ^{249S}	93
3.3.4 Conclusion	93
4 <i>Permeability of withanolides</i>.....	95
4.1 Introduction	97
4.2 Methodology	100
4.2.1 System building	100
4.2.2 Steered molecular dynamics simulations	101
4.2.3 Analysis of the results	102
4.3 Results and discussion.....	104
4.3.1 Description of the POPC-cholesterol membrane	104
4.3.2 Wi-A was permeable through POPC membrane.....	104
4.3.2.1 Hydrogen bonds dynamics	107
4.3.2.2 The initial interaction of Wi-A with the membrane	109
4.3.2.3 Penetration of the hydrophilic layer by Wi-A	110
4.3.2.4 Movement of Wi-A through the lipid bi-layer	111
4.3.2.5 Exit of Wi-A from the membrane	113
4.3.2.6 Change in the area per lipid.....	114
4.3.2.7 Role of the water molecule in the permeability of Wi-A	115
4.3.3 WN failed to cross the POPC membrane	116
4.3.4 Difference in charge distribution in Wi-A and WN led to different permeability	117
4.3.5 Conclusion	118

5 Anti-leishmanial activity of withanolides.....	121
5.1 Background of the study	123
5.2 Computational methods	124
5.2.1 Homology modeling.....	124
5.2.2 Molecular Dynamics Simulations	125
5.2.3 Binding site identification	126
5.2.4 Virtual molecular docking of ligands with LPKC	126
5.2.5 Prime/MM-GBSA binding-free energy calculation	127
5.3 Results and discussion	127
5.3.1 LPKC protein structure modeling and active site prediction	127
5.3.2 Molecular Dynamics simulations of modeled LPKC protein.....	128
5.3.3 Virtual Docking of protein with Wi-A and withanone.....	131
5.3.4 Molecular Dynamics Simulations of complexes	132
5.3.5 Interaction analysis of Wi-A and WN with LPKC protein	133
5.4 Conclusions.....	137
6 Mortalin as a potential anti-cancer target for withanolides.....	139
6.1 Background of this study	141
6.2 Experimental inputs from DAILAB@AIST	143
6.3 Computational Methods.....	146
6.3.1 Comparative modeling of mortalin, Bcl-2 and Bcl-xL proteins.....	146
6.3.2 Docking of mortalin protein with Bcl-2 and Bcl-xL structures.....	147
6.3.3 Molecular dynamics simulation of complexes	147
6.4 Computational results	147
6.5 Discussion	151
7 Conclusion of thesis.....	153
8 References	161
9 Appendices.....	181
10 List of publications from the thesis	185
Peer-reviewed articles	187
Articles under review	187
Articles in preparation.....	187
11 Resume of author.....	189

LIST OF FIGURES

FIGURE 1:1 CLASSIFICATION OF WITHANOLIDES	6
FIGURE 2:1 PRINCIPLE BEHIND TARGETING CANCER BY WITHANOLIDES	21
FIGURE 2:2 OVERVIEW OF THE METHODOLOGY	22
FIGURE 2:3 SCHEMATIC REPRESENTATION OF THE TARGET IDENTIFICATION METHODS	24
FIGURE 2:4 SCHEMATIC REPRESENTATION OF TARGET STRUCTURE IDENTIFICATION TECHNIQUES.....	25
FIGURE 2:5 REQUIREMENTS FOR THE PROCESS OF MOLECULAR DOCKING SIMULATIONS.....	29
FIGURE 2:6 THE PROCESS OF MOLECULAR DOCKING	30
FIGURE 2:7 WI-A AND WN TOGETHER ARE TOXIC TO CANCER CELLS.....	40
FIGURE 2:8 EFFECT OF WI-A AND WN ON THE VEGF EXPRESSION.....	41
FIGURE 2:9 INTERACTION DIAGRAM OF KH3 DOMAIN OF hnRNP-K PROTEIN WITH ssDNA	44
FIGURE 2:10 INTERACTIONS OF WI-A AND WN WITH KH3 DOMAIN OF hnRNP-K.....	45
FIGURE 2:11 TWO POSSIBLE BINDING CONFORMATIONS OF WN	45
FIGURE 2:12 RMSD OF WI-A	46
FIGURE 2:13 BINDING OF WI-A AT THE KH3 DOMAIN OF hnRNP-K AFTER THE MD SIMULATION.....	47
FIGURE 2:14 WITHANONE_C1 BINDING CONFORMATION OF WN AFTER MD SIMULATION .	47
FIGURE 2:15 STRUCTURES OF WI-A AND TUBOCAPSANOLIDE-A.....	51
FIGURE 2:16 SUPERIMPOSED BINDING POSES OF TA, WN AND WI-A AT THE C-TERMINAL OF HSP90	54
FIGURE 2:17 SIMILAR BINDING POSES OF TA AND WN AT THE C-TERMINAL OF HSP90.....	55
FIGURE 2:18 INTERACTIONS OF TA WITH C-TERMINAL OF HSP 90.....	56
FIGURE 2:19 2D REPRESENTATION OF TA-HS90 BINDING INTERACTIONS	56
FIGURE 2:20 INTERACTIONS OF WN WITH C-TERMINAL OF HSP 90	57
FIGURE 2:21 2D REPRESENTATION OF WN-HSP90 BINDING INTERACTIONS.....	57
FIGURE 2:22 INTERACTIONS OF WI-A WITH C-TERMINAL OF HSP90.....	58
FIGURE 2:23 2D REPRESENTATION OF WI-A AND HSP90 BINDING INTERACTIONS	58
FIGURE 2:24 DIFFERENT UNSATURATED KETONE CONTAINING WITHANOLIDES BOUND AT THE C-TERMINAL OF HSP90	60

FIGURE 2:25 DOWNREGULATION OF MRN COMPLEX PROTEINS BY WI-A	64
FIGURE 2:26 BINDING OF WI-A WITH MYC-MAX AND MAD-MAX COMPLEXES	68
FIGURE 2:27 BINDING OF WI-A AT DNA BINDING POCKET OF MYC-MAX AND MAD-MAX COMPLEXES.....	68
FIGURE 2:28 RESULTS FROM THE MD SIMULATIONS OF WI-A WITH MYC-MAX AND MAD- MAX COMPLEXES.....	69
FIGURE 2:29 STABILIZED WI-A IN DNA-BOUND MYC-MAX (LEFT) AND MAD-MAX (RIGHT) AFTER 50NS MD SIMULATION	70
FIGURE 2:30 H-BOND DYNAMICS DURING THE MD SIMULATIONS	71
FIGURE 3:1 THREE DOMAINS OF P53 PROTEIN	79
FIGURE 3:2 STRUCTURAL COMPARISON BETWEEN P53 ^W AND P53 ^{143A}	82
FIGURE 3:3 EFFECT OF WI-A ON P53 ^{143A} AND P53 ^{249S} MUTANT CELL LINES	83
FIGURE 3:4 DIFFERENCE IN THE MOLECULAR SURFACE NEAR Y220 SITE IN P53 ^W AND ^U P53 ^{220C}	84
FIGURE 3:5 WATER NETWORK NEAR THE 220 TH RESIDUE IN P53 ^W AND ^U P53 ^{220C} PROTEIN ...	85
FIGURE 3:6 BINDING OF THE WITHANOLIDES WITH P53 ^W NEAR TYR 220 RESIDUE.....	87
FIGURE 3:7 INTERACTIONS OF WI-A WITH P53 ^{220C} NEAR CYS 220	89
FIGURE 3:8 INTERACTIONS OF WN WITH P53 ^{220C} PROTEIN STRUCTURE	89
FIGURE 3:9 CHARGE COMPLEMENTARITY OF WI-A AND WN WITH THE BINDING CAVITY ..	90
FIGURE 3:10 EFFECT OF WI-A ON P53 ^W AND P53 ^{220C} CONTAINING CELL LINES	90
FIGURE 3:11 SUPERIMPOSED VIEW OF THE MUTATION SITE OF P53 ^W AND P53 ^{249S}	92
FIGURE 3:12 ROOT MEAN SQUARE DEVIATIONS OF RESIDUES OF P53 ^W AND P53 ^{249S}	92
FIGURE 4:1 POPC-CHOLESTEROL MEMBRANE DESCRIPTION	104
FIGURE 4:2 INDEPENDENCE OF WI-A ON ITS INITIAL ORIENTATION	105
FIGURE 4:3 TIME VS AVERAGE DISTANCE GRAPH FOR WI-A DURING SMD SIMULATIONS	106
FIGURE 4:4 TIME-FORCE AND DISTANCE-FORCE GRAPH OF WI-A SMD SIMULATIONS	107
FIGURE 4:5 HYDROGEN BONDS DYNAMICS OF WI-A WITH WATER AND POPC MEMBRANE	107
FIGURE 4:6 RELATION OF APPLIED FORCE WITH THE H-BOND NETWORK OF WI-A DURING THE PERMEATION	108

FIGURE 4:7 WI-A IN THE COMPLETE SOLVATED STATE	109
FIGURE 4:8 INITIAL INTERACTIONS OF WI-A WITH THE POPC MEMBRANE.....	110
FIGURE 4:9 PENETRATION OF THE HYDROPHILIC LAYER BY WI-A	111
FIGURE 4:10 ENTRY OF WI-A INTO THE HYDROPHOBIC CORE OF THE MEMBRANE.....	112
FIGURE 4:11 PORE ON THE SURFACE OF THE MEMBRANE.....	112
FIGURE 4:12 INITIATION OF EXIT OF WI-A FROM THE HYDROPHOBIC CORE OF THE MEMBRANE	113
FIGURE 4:13 EXIT OF THE WI-A FROM MEMBRANE.....	114
FIGURE 4:14 ROLE OF WATER MOLECULES IN THE PERMEATION OF WI-A.....	116
FIGURE 4:15 INITIAL ORIENTATION OF WN WITH THE POPC-CHOLESTEROL MEMBRANE.	117
FIGURE 4:16 CHARGE DISTRIBUTION OVER THE SURFACE OF WI-A AND WN	118
FIGURE 5:1 RMSD TRAJECTORY OF THE MODELED LPKC PROTEIN BACKBONE DURING THE 15NS LONG MD SIMULATIONS	128
FIGURE 5:2 RMSD IN THE ROG OF LPKC PROTEIN DURING THE 15NS LONG MD SIMULATIONS	129
FIGURE 5:3 ALL ATOM SUPERIMPOSITION OF MODELED LPKC PROTEIN STRUCTURE BEFORE AND AFTER THE SIMULATION	130
FIGURE 5:4 VARIATION IN NUMBER OF INTRA H-BONDS DURING THE 15NS MD SIMULATIONS OF LPKC	130
FIGURE 5:5 ROOT MEAN SQUARE FLUCTUATION (RMSF) OF ALL RESIDUES OF LPKC PROTEIN DURING THE MD SIMULATIONS.....	131
FIGURE 5:6 DOCKING COMPLEXES OF LPKC WITH NATURAL COMPOUNDS:.....	132
FIGURE 5:7 RMSD TRAJECTORY OF THE WITHA FERIN A IN WI-A & LPKC COMPLEX (RED) AND WITHANONE IN WITHANONE-LPKC COMPLEX (GREEN).....	133
FIGURE 5:8 INTERACTIONS BETWEEN LPKC AND WI-A	135
FIGURE 5:9 INTERACTIONS BETWEEN LPKC AND WN.....	136
FIGURE 6:1 CO-IMMUNOPRECIPITATION OF BCL-2 AND BCL-xL WITH MORTALIN	144
FIGURE 6:2 EXPRESSION ANALYSIS OF MORTALIN AND p53 IN BCL-xL AND BCL-2 OVEREXPRESSING CELLS	145
FIGURE 6:3 MORTALIN-p53 COMPLEXES IN BCL-2 AND BCL-xL OVEREXPRESSING CELLS	146

FIGURE 6:4 STRUCTURAL CHANGES IN MORTALIN-BCL-2 COMPLEX DURING MD SIMULATIONS	150
FIGURE 6:5 STRUCTURAL CHANGES IN MORTALIN-BCL-XL COMPLEX AFTER MD SIMULATIONS	151

LIST OF TABLES

TABLE 1:1 CLASSIFICATION OF WITHANOLIDES.	6
TABLE 2:1 DOCKING SCORES OF WITHANOLIDES AT THE C-TERMINAL OF HSP90.	54
TABLE 2:2 DOCKING SCORES OF WI-A AND MYC/MAD-DNA	66
TABLE 3:1 PDB IDS OF DIFFERENT P53 PROTEIN VARIANTS AND THEIR STRUCTURAL RESOLUTION.....	81
TABLE 3:2 DOCKING SCORES (XP DOCKING) OF WITHANOLIDES AND PHIKAN WITH P53 ^W AND P53 ^{220C}	86
TABLE 3:3 H-BOND NETWORK AROUND 249 RESIDUE IN P53 ^W AND P53 ^{249S}	91
TABLE 3:4 BINDING SCORE OF WI-A AND WN WITH DIFFERENT P53 MUTANTS OF DNA BINDING SITE.....	93
TABLE 4:1 CHANGE IN THE AREA PER LIPID DURING THE WI-A PERMEABILITY.....	115
TABLE 5:1 XP DOCKING SCORES AND BINDING ENERGIES OF LPKC WITH NATURAL COMPOUNDS.....	131
TABLE 5:2 INTERACTION PROFILE OF LPKC WITH WI-A AND WN	133
TABLE 6:1 PREDICTION OF INTERACTING AMINO ACID RESIDUES OF PROTEINS	146
TABLE 6:2 LIST OF FUNCTIONAL RESIDUES AT THE INTERFACE OF MORTALIN, BCL-2 AND BCL-XL PROTEINS.....	147
TABLE 6:3 INTERFACIAL RESIDUES IN DOCKED PROTEIN–PROTEIN COMPLEXES BEFORE MD SIMULATIONS	148
TABLE 6:4 INTERFACIAL RESIDUES IN DOCKED PROTEIN–PROTEIN COMPLEXES AFTER MD SIMULATIONS	149

LIST OF EQUATIONS

EQUATION 2:1 FORMULA TO CALCULATE BINDING FREE ENERGY USING MMGB/PBSA	35
EQUATION 2:2 FORMULA TO CALCULATE ΔG VALUE OF A MOLECULE USING ITS MECHANICAL ENERGY.....	35
EQUATION 2:3 FORMULA TO CALCULATE THE AVERAGE ENERGY OF A MOLECULE	35
EQUATION 2:4 FORMULA TO CALCULATE PRIME/MMGBSA FREE ENERGY	35
 EQUATION 4:1 CALCULATION OF THE PERCENTAGE OF H-BONDS DURING SMD SIMULATIONS	 103
EQUATION 4:2 EXPRESSION TO CALCULATE AREA PER LIPID	103

LIST OF ABBREVIATIONS AND ACRONYMS

AIST	The National Institute of Advanced Industrial Science and Technology
ALT	Alternate mechanism of lengthening of Telomeres
APL	Area per lipid
COM	Center of mass
DAILAB	DBT-AIST International Laboratory for Advanced Biomedicine
DBD	DNA binding domain
hnRNP-K	Heterogeneous nuclear riboprotein-K
HSP90	Heat-shock protein 90
L PKC	Leishmanial protein kinase C
MD	Molecular dynamics
MRN	MRE11-RAD50-NBS1
p53 ^{143A}	V143A p53 mutant
p53 ^{220C}	Y220C p53 mutant with an inhibitor
p53 ^{249S}	R249S p53 mutant
p53 ^{273C}	R273C p53 mutant
p53 ^{273H}	R273H p53 mutant
p53 ^w	Wild type p53
POPC	1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
RMSD	Root mean square deviation
RMSF	Root mean square fluctuation
ROG	Radius of gyration
SASA	Solvent accessible surface area
SMD	Steered molecular dynamics
SP	Standard precision
TA	Tubocapsanolide-A
TEP	Telomerase plus
^u p53 ^{220C}	Unbound Y220C mutant
Wi-A	Withaferin-A
WN	Withanone
XP	Extra precision